Per the KFF 2025 Employer Health Benefits Survey, 43% of firms with 5,000-plus employees cover GLP-1s for weight loss (up from 28%), 30% of firms with 1,000 to 4,999, and 16% of firms with 200 to 999
MalhotraALucia FuentesAEdwardsBA
Many effects associated with retatrutide are dose-dependent, meaning they may be more or less relevant at different stages of your treatment protocol
What You Can Do While Waiting Options Available Now Option 1: Start Existing GLP-1 Medications - Wegovy (semaglutide): 15% weight loss, available now
LVG was an advisory board member for Novo Nordisk and Eli Lilly, and has done commercially sponsored research for Novo Nordisk
She continues, "The cardiovascular protection and other emerging benefits, such as improvements in outcomes related to metabolic-associated liver disease and obstructive sleep apnea, are additional benefits of these medications." About the Author Jennifer Fisher, MMSc, PA-C, Health Writer About the Reviewer Chika V